Title:
ANTI-FGL1 ANTIBODY AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/007543
Kind Code:
A1
Abstract:
Disclosed are an anti-FGL1 antibody or an antigen-binding fragment thereof, and uses and pharmaceutical compositions thereof. The anti-FGL1 antibody of the present invention can bind to FGL1 specifically, block the binding of FGL1 to LAG-3, reverse the inhibitory effect of FGL1 on T cells, and activate T cells to secrete cytokines.
Inventors:
ZHOU CHONG (CN)
JIANG XIAOLING (CN)
WANG YIZHEN (CN)
HUANG ZHENZHEN (CN)
WU CHONGBING (CN)
JIANG XIAOLING (CN)
WANG YIZHEN (CN)
HUANG ZHENZHEN (CN)
WU CHONGBING (CN)
Application Number:
PCT/CN2021/097569
Publication Date:
January 13, 2022
Filing Date:
June 01, 2021
Export Citation:
Assignee:
SHENGHE CHINA BIOPHARMACEUTICAL CO LTD (CN)
International Classes:
A61K39/395; C07K16/36; A61P35/00; A61P37/00; C12N15/13
Other References:
JUN WANG, SANMAMED MIGUEL F., DATAR ILA, SU TINA TIANJIAO, JI LAN, SUN JINGWEI, CHEN LING, CHEN YUSHENG, ZHU GEFENG, YIN WEIWEI, Z: "Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3", CELL, ELSEVIER, AMSTERDAM NL, vol. 176, no. 1-2, 10 January 2019 (2019-01-10), Amsterdam NL , pages 334 - 347.e12, XP055629972, ISSN: 0092-8674, DOI: 10.1016/j.cell.2018.11.010
Download PDF: